PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once
daily for 3 months, blinded towards the administration of progestin or placebo after end of
PGL4001 treatment.